Skip to main content
. 2020 Dec 6;14(1):100977. doi: 10.1016/j.tranon.2020.100977

Fig. 1.

Fig. 1

PFS and OS by IHC-based PD-L1 expression in patients with DLBCL (A and B) and GCB DLBCL (C and D). The numbers below the X-axis depict patients at risk of progression who had elevated PD-L1 and those who did not have elevated PD-L1. DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell–like; IHC, immunohistochemistry; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.

HHS Vulnerability Disclosure